Get the Stockscreener App
5.69
0.18%
0.01
Intercure Ltd stock is traded at $5.69, with a volume of 3,433.
It is up +0.18% in the last 24 hours and up +518.81% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
See More
Previous Close:
$5.68
Open:
$5.69
24h Volume:
3,433
Relative Volume:
0.08
Market Cap:
$338.49M
Revenue:
$117.93M
Net Income/Loss:
$5.00M
P/E Ratio:
43.30
EPS:
0.1314
Net Cash Flow:
$-12.91M
1W Performance:
+568.23%
1M Performance:
+518.81%
6M Performance:
+585.54%
1Y Performance:
+251.71%
1-Day Range:
$5.69
$5.89
1-Week Range:
$4.80
$6.10
52-Week Range:
$0.68
$6.10
Intercure Ltd Stock (INCR) Company Profile
Compare INCR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
5.715 | 51.47M | 117.93M | 5.00M | -12.91M | 0.1314 |
TAK
Takeda Pharmaceutical Co Adr
|
17.99 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.04 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.59 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.62 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
516.18 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
Intercure (INCR) Chart: Adds 0.23% to Close at $0.87 in the Current Update; Technical Setup: Traders Can Monitor the $0.83-$0.91 Range in Latest TradingMax Pain Level - dars.gov.et
InterCure announces 1-for-5 reverse stock split starting Monday By Investing.com - Investing.com Australia
Intercure (NASDAQ: INCR) issues stock for ISHI deal's first closing - Stock Titan
BRIEF-Intercure Ltd. Announces 1-For-5 Reverse Share Split - Bitget
InterCure announces 1-for-5 reverse stock split starting Monday - Investing.com
InterCure Ltd. Announces 1-for-5 Reverse Share Split - The Manila Times
Intercure Ltd. (INCR) Slips to $0.96: Support Test Looms as Cannabis Stock Faces PressureRVOL Spike - dars.gov.et
InterCure Ltd (INCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alon Shmuel Granot Net Worth (2026) - GuruFocus
InterCure Shareholders Approve Proposal at August 11 Extraordinary Meeting - TipRanks
InterCure holds extraordinary shareholder meeting - Bitget
InterCure Ltd. (INCR) shareholders back proposal at August 11, 2026 special meeting - Stock Titan
Intercure (INCR) Advances 5.91% to $0.98, Approaching Key Resistance at $1.03Factor Crowding - vinanet.vn
InterCure Ltd (INCR) Stock News Today - TradingKey
InterCure Ltd (INCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intercure Ltd. Ordinary Shares Share Price Live Today – NASDAQ:INCR Stock Price, Chart, News, History - Upstox
Intercure (INCR) Slips 1.16% to $0.95, Hovering Above Key SupportRVOL Spike - dars.gov.et
Intercure Details Voting Procedures for August 11 Extraordinary Shareholder Meeting - TipRanks
InterCure (INCR) sets voting process for August 11 extraordinary shareholder meeting - Stock Titan
INCR Q2 2023 Earnings: EPS Surprises to the Upside Despite Stock DeclineAdjusted Earnings Analysis - vinanet.vn
InterCure Ltd. Revenue Breakdown – TASE:INCR - TradingView
InterCure Ltd (INCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InterCure Ltd (INCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InterCure Ltd (INCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InterCure Ltd (INCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InterCure Ltd (INCR) Income Statement - TradingKey
INCR|InterCure Ltd|Price:0.939|Chg%:-0.020 - TradingKey
INCR|InterCure Ltd|Price:0.927|Chg%:+0.025 - TradingKey
InterCure Ltd (INCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INCR Q2 2023 Earnings: EPS Surprises to the Upside as Profitability Exceeds ExpectationsHealthcare Earnings Report - vinanet.vn
What Is Driving InterCure (NASDAQ:INCR) on the Nasdaq? - Kalkine Media
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beats Estimates by 28.7% as Stock GainsRevenue Growth Outlook - dars.gov.et
InterCure (INCR) seeks approval for 5-for-1 reverse share split - Stock Titan
Alexander Rabinovich Net Worth (2026) - GuruFocus
Lennie Grinbaum Michelson Net Worth (2026) - GuruFocus
INCR Q2 2023 Earnings: EPS Surprise Beats Estimates Amid Undisclosed RevenueAnnual Earnings Summary - vinanet.vn
Price to book forward of Intercure Ltd. – NASDAQ:INCR - TradingView
ETFs Investing in InterCure Ltd. Stocks - TradingView
Intercure Ltd. (INCR) Slides 3% as Support at $0.90 Comes Into FocusFibonacci Entry Signals - dars.gov.et
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Surges Past Estimates with 28.68% SurpriseCost Structure Review - dars.gov.et
InterCure Ltd. Actuals & Estimates (TASE:INCR) - TradingView
Price to earnings forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd. Actuals & Estimates (BOATS:INCR) - TradingView
Intercure (INCR) Sees Modest Decline, Tests Key Support Near $1.00Dark Pool Sentiment - po-news-eg.net
Price to sales forward of InterCure Ltd. – TASE:INCR - TradingView
Enterprise value to EBITDA forward of InterCure Ltd. – TASE:INCR - TradingView
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beats Estimates by 28.7% Amid Uncertain Revenue PictureEnergy Earnings Report - dars.gov.et
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds - Sahm
InterCure Secures NIS 22 Million Private Placement to Fund Global Medical Cannabis Expansion - The Globe and Mail
InterCure secures $7.4M funding commitment, may rise to $18.6M - Investing.com UK
InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. - marketscreener.com
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):